Wikipedia

Levosulpiride

Levosulpiride, sold under the brand names Dislep and Sulpepta among others, is a dopamine antagonist medication which is used in the treatment of psychotic disorders like schizophrenia, major depressive disorder, nausea and vomiting, and gastroparesis.[1][2][3][4] It is taken by mouth.

Levosulpiride
Clinical data
Trade namesDislep, Sulpepta, others
Other namesL-Sulpiride; S-(–)-Sulpiride; RV-12309
Routes of
administration		Oral
ATC code
Identifiers
  • N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H23N3O4S
Molar mass341.43 g·mol−1
3D model (JSmol)
  • CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
  • InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
  • Key:BGRJTUBHPOOWDU-NSHDSACASA-N
  (verify)

It is a selective antagonist of the dopamine D2 receptor and an agonist of the serotonin 5-HT4 receptor.[4][5] Chemically, it is a benzamide and the (S)-(−)-enantiomer of sulpiride.[4]

Levosulpiride is marketed widely throughout the world, including in Europe, South Korea, Latin America, India, and Pakistan.[2] It is not available in the United States or the United Kingdom.[2]

Medical uses

edit

Levosulpiride is used in the treatment of:[3][1]

Levosulpiride is not currently licensed for treatment of premature ejaculation in the United Kingdom or other European countries.[8]

Side effects

edit

Side effects of levosulpiride include amenorrhea, gynecomastia, galactorrhea, changes in libido, and neuroleptic malignant syndrome.[9] In the United States, as of 2013 only one case of adverse reaction to levosulpiride had been recorded on the FDA Adverse Event Reporting System Database.[8] A case of rapid-onset resistant dystonia caused by low-dose levosulpiride was reported in India.[10]

Pharmacology

edit

Pharmacodynamics

edit

Levosulpiride is a selective dopamine D2 receptor antagonist.[4] The drug has also been found to act as a moderate agonist of the serotonin 5-HT4 receptor.[5] It is said to have antipsychotic, antidepressant, antiemetic, and gastroprokinetic effects.[4]

Chemistry

edit

Levosulpiride is a substituted benzamide derivative.[4] It is the levorotatory enantiomer of sulpiride.[4] Other benzamide derivatives include amisulpride, metoclopramide, tiapride, sultopride, and veralipride, among others.

References

edit
  1. ^ a b "Levosulpiride". AdisInsight. 24 October 2021. Retrieved 22 October 2024.
  2. ^ a b c "Levosulpiride (International database)". Drugs.com. 6 October 2024. Retrieved 22 October 2024.
  3. ^ a b Mucci A, Nolfe G, Maj M (February 1995). "Levosulpiride: a review of its clinical use in psychiatry". Pharmacol Res. 31 (2): 95–101. doi:10.1016/1043-6618(95)80053-0. PMID 7596960.95-101&rft.date=1995-02&rft_id=info:doi/10.1016/1043-6618(95)80053-0&rft_id=info:pmid/7596960&rft.aulast=Mucci&rft.aufirst=A&rft.au=Nolfe,+G&rft.au=Maj,+M&rfr_id=info:sid/en.wikipedia.org:Levosulpiride" class="Z3988">
  4. ^ a b c d e f g Rossi F, Forgione A (February 1995). "Pharmacotoxicological aspects of levosulpiride". Pharmacol Res. 31 (2): 81–94. doi:10.1016/1043-6618(95)80052-2. PMID 7596959.81-94&rft.date=1995-02&rft_id=info:doi/10.1016/1043-6618(95)80052-2&rft_id=info:pmid/7596959&rft.aulast=Rossi&rft.aufirst=F&rft.au=Forgione,+A&rfr_id=info:sid/en.wikipedia.org:Levosulpiride" class="Z3988">
  5. ^ a b Tonini M, De Giorgio R, Spelta V, Bassotti G, Di Nucci A, Anselmi L, Balestra B, De Ponti F (April 2003). "5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract". Dig Liver Dis. 35 (4): 244–250. doi:10.1016/s1590-8658(03)00061-6. PMID 12801035.244-250&rft.date=2003-04&rft_id=info:doi/10.1016/s1590-8658(03)00061-6&rft_id=info:pmid/12801035&rft.aulast=Tonini&rft.aufirst=M&rft.au=De+Giorgio,+R&rft.au=Spelta,+V&rft.au=Bassotti,+G&rft.au=Di+Nucci,+A&rft.au=Anselmi,+L&rft.au=Balestra,+B&rft.au=De+Ponti,+F&rfr_id=info:sid/en.wikipedia.org:Levosulpiride" class="Z3988">
  6. ^ Arshad A, Irfan M, Inam M, Hussain NH, Ismail SB (2022). "Levosulpiride for Premature Ejaculation: A Systematic Review and Meta-Analysis". Am J Mens Health. 16 (5): 15579883221124832. doi:10.1177/15579883221124832. PMC 9515538. PMID 36154321.
  7. ^ Greco E, Polonio-Balbi P, Speranza JC (August 2002). "Levosulpiride: a new solution for premature ejaculation?". Int J Impot Res. 14 (4): 308–309. doi:10.1038/sj.ijir.3900901. PMID 12152121.308-309&rft.date=2002-08&rft_id=info:doi/10.1038/sj.ijir.3900901&rft_id=info:pmid/12152121&rft.aulast=Greco&rft.aufirst=E&rft.au=Polonio-Balbi,+P&rft.au=Speranza,+JC&rfr_id=info:sid/en.wikipedia.org:Levosulpiride" class="Z3988">
  8. ^ a b Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, et al. (June 2013). "Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database". Drug Safety. 36 (6): 467–79. doi:10.1007/s40264-013-0032-z. PMC 3664739. PMID 23553446.467-79&rft.date=2013-06&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664739#id-name=PMC&rft_id=info:pmid/23553446&rft_id=info:doi/10.1007/s40264-013-0032-z&rft.aulast=Poluzzi&rft.aufirst=E&rft.au=Raschi,+E&rft.au=Koci,+A&rft.au=Moretti,+U&rft.au=Spina,+E&rft.au=Behr,+ER&rft.au=Sturkenboom,+M&rft.au=De+Ponti,+F&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664739&rfr_id=info:sid/en.wikipedia.org:Levosulpiride" class="Z3988">
  9. ^ "Levosulpiride drug information". DrugsUpdate India.
  10. ^ Naskar S, Nath K (January 2007). "Rapid onset resistant dystonia with low dose of Levosulpiride". British Journal of Psychiatry. 190 (1): 81. doi:10.1192/bjp.190.1.81a.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Levosulpiride&oldid=1269325033"